



REVIEW

New advances in perioperative cardioprotection [version 1; peer review: 2 approved]

Mona Momeni ¹, Stefan De Hert ²

¹Department of Anesthesiology & Acute Medicine, Cliniques universitaires Saint Luc, Université Catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Avenue Hippocrate, Brussels, 1200, Belgium

²Department of Anesthesiology & Perioperative Medicine, Ghent University Hospital, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium

v1 **First published:** 24 Apr 2019, 8(F1000 Faculty Rev):538 (<https://doi.org/10.12688/f1000research.17184.1>)

Latest published: 24 Apr 2019, 8(F1000 Faculty Rev):538 (<https://doi.org/10.12688/f1000research.17184.1>)

Abstract

With the increasing age of the general population, medical conditions necessitating a surgical intervention will increase. Concomitant with advanced age, the prevalence of type 2 diabetes mellitus will also increase. These patients have a two- to three-fold higher risk of occurrence of cardiovascular events and are at higher risk of perioperative myocardial ischemia. This review will discuss recent advances in the field of perioperative cardioprotection and focus specifically on strategies that have aimed to protect the diabetic and the aged myocardium. This review will not deal with potential putative cardioprotective effects of opioids and anesthetic agents, as this is a very broad area that would necessitate a dedicated overview.

Keywords

Cardioprotection, Aging, Diabetes Mellitus

Open Peer Review

Referee Status:

	Invited Referees	
	1	2
version 1 published 24 Apr 2019		

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Arthur Bouwman**, Catharina Hospital, The Netherlands
- 2 **Gerd Heusch**, University of Essen Medical School, Germany

Any comments on the article can be found at the end of the article.

Corresponding author: Mona Momeni (mona.momeni@uclouvain.be)

Author roles: **Momeni M:** Conceptualization, Methodology, Resources, Writing – Original Draft Preparation; **De Hert S:** Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Momeni M and De Hert S. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Momeni M and De Hert S. **New advances in perioperative cardioprotection [version 1; peer review: 2 approved]** F1000Research 2019, **8**(F1000 Faculty Rev):538 (<https://doi.org/10.12688/f1000research.17184.1>)

First published: 24 Apr 2019, **8**(F1000 Faculty Rev):538 (<https://doi.org/10.12688/f1000research.17184.1>)

Introduction

According to the US Census Bureau's 2017 National Population Projections, there will be 78 million people 65 years or older in the US by 2035¹. Elderly people are a growing part of surgical caseloads².

Also, with increasing age, the prevalence of ischemic heart disease increases. Ischemic heart disease is one of the leading causes of death worldwide³. Similarly, the prevalence of type 2 diabetes mellitus increases in the proportion of people older than 65 years of age⁴. Cardiovascular disease, especially ischemic heart disease, is an important risk factor of morbidity and mortality in patients with diabetes⁵.

In this review, we outline recent cardioprotective strategies in patients with diabetes and in the elderly and discuss their eventual application in the perioperative setting. For a complete overview of the cardioprotective effects of routinely used anesthetics and other pharmacological agents commonly used in the perioperative period, we encourage the reader to address other systematic and narrative reviews in this field⁶⁻¹⁴.

Type 2 diabetes mellitus

Ischemia-reperfusion injury and cardioprotection in diabetes

Reperfusion of the ischemic myocardium is the main key to saving tissue. Nevertheless, reperfusion may result in harmful effects, known as reperfusion injury. The main mechanisms involved in the pathogenesis of reperfusion injury are calcium overload and oxidative stress with the production of reactive oxygen species. Other mechanisms are mitochondrial dysfunction, inflammation, apoptosis, endoplasmic reticulum stress, and protein kinase activation^{15,16}.

Patients with diabetes seem especially vulnerable to the effects of myocardial ischemia-reperfusion injury. The exact underlying mechanisms are not fully known but an increased basal oxidative stress due to excessive reactive oxygen species production or reduced endogenous antioxidant defense system or both seem to play an important role¹⁷. The enhanced basal oxidative stress is thought to be the result of chronic hyperglycemia. Chronic hyperglycemia as such severely impacts the ischemic myocardium. It is associated with endothelial dysfunction, impairs the development of coronary collateral blood flow, and attenuates the dilatation of coronary microcirculation in response to ischemia and to increased myocardial oxygen consumption¹⁸. In addition, animal and human data support the concept that ischemic and anesthetic cardioprotective strategies are not effective in diabetic hearts¹⁹⁻²³. Hyperglycemia further impairs the pharmacological activation of mitochondrial ATP-dependent potassium (K_{ATP}) channels, responsible for preconditioning effects²⁴. Moreover, many patients with diabetes take sulfonylurea hypoglycemic agents which close the K_{ATP} channels. As activation of these channels is one of the mechanisms that protect the myocardium against ischemia-reperfusion injury, its blocking may explain the impaired cardioprotective effects of preconditioning strategies observed in many patients with diabetes.

Metformin and its cardioprotective actions

Metformin is an oral anti-diabetic drug that is widely used in patients with diabetes. Its glucose-lowering effects result from various actions: inhibition of complex I of the mitochondrial respiratory chain, decreased hepatic glucose production, increased glucose reuptake, and stimulation of adenosine monophosphate-activated protein kinase (AMPK)²⁵. The main concern with the use of metformin in the perioperative period has been the development of lactic acidosis.

Interestingly, recent data show evidence for cardioprotective effects of metformin²⁶. The main action of metformin seems to be via activation of AMPK, which increases tolerance against ischemia-reperfusion injury. Activation of AMPK further results in phosphorylation of endothelial nitric oxide synthase (eNOS), increasing nitric oxide (NO) bioavailability and preventing mitochondrial permeability transition pore (mPTP) opening at reperfusion. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation seems to be essential in the pathophysiology of different cardiovascular diseases and explains the beneficial effects on ischemia-reperfusion injury and heart failure²⁷. In addition, metformin stimulates intracellular formation of adenosine. Adenosine receptor stimulation activates the reperfusion injury salvage kinase (RISK) pathway, which in turn contributes to eNOS phosphorylation and prevents opening of mPTP^{28,29}. Although beneficial effects of metformin on ischemia-reperfusion injury have been extensively shown in various small-animal models³⁰⁻³⁵, such effects could not be reproduced in swine models³⁶.

This is another example that data obtained on rodents should be confirmed by similar findings in larger-animal models before translating them into human research³⁷⁻³⁹.

They, moreover, highlight the influence of anesthetic agents when used in cardioprotective research. Indeed, in the study by Techiryan *et al.*³⁶, the pigs were maintained anesthetized with a continuous infusion of propofol. In a rat model, sevoflurane in the presence of low sedative propofol concentrations completely lost its protection⁴⁰. Otherwise, propofol has been shown to interfere with the cardioprotective mechanisms induced by remote ischemic preconditioning (RIPC)^{41,42}. It is therefore plausible that propofol also interferes with other forms of cardioprotection.

Metformin and clinical outcome data

Given its theoretical cardioprotective effects, metformin has been extensively studied in recent years. Many prospective and retrospective studies have shown the efficacy of metformin in decreasing cardiovascular events, mortality, and hospital readmission rates in patients with heart failure and diabetes⁴³⁻⁴⁹ and in patients with coronary artery disease and diabetes⁵⁰⁻⁵⁴. In non-diabetic patients, however, metformin seemed not to be associated with any beneficial effects in terms of cardiovascular outcome⁵⁵⁻⁵⁹. Whether in clinical practice the cardioprotective properties of metformin are more pronounced in diabetic hearts should be further investigated.

Otherwise, the positive effects of metformin were mostly obvious when it was used as chronic treatment. In trials where metformin was solely started before the initiation of the study, no beneficial effects could be observed.

In clinical practice, chronic metformin therapy in diabetic patients presenting for surgery is stopped because of the fear of perioperative lactic acidosis. In the era of perioperative cardioprotection, it is questionable whether this is justified. So far, no studies have investigated this issue.

Newer anti-hyperglycemic medications and cardiovascular outcome data

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are two new classes of anti-hyperglycemic agents^{60,61}. Sodium-glucose cotransporter-2 inhibitors function by increasing urinary excretion of glucose in the renal tubules. Glucagon-like peptide-1 receptor agonists execute their function on the basis of the incretin effect, a response to release more insulin because of high glucose levels after a meal. The cardiovascular safety of both agents has been extensively evaluated in recent years. Although the results of randomized controlled trials with these new agents show cardiovascular safety, their beneficial effects in terms of cardiovascular outcome warrant further investigation^{62,63}.

Remote ischemic preconditioning and diabetes

RIPC is a technique during which brief periods of ischemia in a remote vascular bed provide protection against ischemia-reperfusion injury in different parenchymal organs. The most studied organ so far is the heart. It is beyond the scope of this review to discuss the putative mechanisms involved and the conflicting results of clinical trials on RIPC. The interested reader is referred to different review articles on the topic^{9,64–67}. The CONDI 2/ERIC-PPCI trial (ClinicalTrials.gov Identifier: NCT02342522), a large European multicenter study, is investigating whether remote ischemic conditioning prior to percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction will decrease the rates of cardiac mortality and hospitalization for heart failure at 12 months.

Whether RIPC can have any positive influence on the diabetic myocardium has been evaluated in only a few trials. One of the studies that have specifically addressed this issue is a retrospective analysis⁶⁸ which showed that RIPC has no cardioprotective effects in patients with diabetes and may even be deleterious in those diabetics who received sulfonylurea hypoglycemic agents.

Recently, the EUROpean and Chinese Cardiac and Renal Remote Ischemic Preconditioning Study (EURO-CRIPS) has sought to determine whether RIPC could be cardioprotective in the presence of diabetes⁶⁹. Among 223 patients who underwent a percutaneous coronary intervention, 38% had diabetes mellitus. Periprocedural myocardial infarction occurred in a significantly higher number of patients with diabetes in the control group compared with the RIPC group.

The Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery (ERICCA) study⁷⁰ and the Remote Ischemic Preconditioning for Heart Surgery (RIPHeart) study⁷¹ have looked at this issue as well. In both studies, the incidence of primary endpoint (death from cardiovascular causes, non-fatal myocardial infarction, coronary revascularization, or stroke for the ERICCA study and composite of death, myocardial infarction, stroke, or acute renal failure for the RIPHeart study) was similar between diabetic patients assigned to the control group and those assigned to the RIPC group.

Nevertheless, the use of propofol—known to interfere with the cardioprotective effects of remote ischemic conditioning—in both studies might have influenced their results⁷². Therefore, further research and well-designed clinical trials are needed to seek whether diabetic myocardium is responsive to the cardioprotective effects of RIPC.

Beta-blockers and their cardioprotective effects in diabetes

Beta-blockers are recommended as cardioprotective medication in patients with coronary artery disease⁷³ and congestive heart failure⁷⁴. Indeed, their use is associated with reduced mortality and reduced recurrent myocardial infarction after myocardial infarction. Beta-blockers decrease mortality as well in patients with chronic heart failure and systolic dysfunction. Patients with diabetes often present different cardiovascular risk factors. The Diabetes Postoperative Mortality and Morbidity (DIPOM) trial evaluated the long-term effects of 100 mg metoprolol or placebo on mortality and morbidity in diabetic patients undergoing major non-cardiac surgery⁷⁵. This study was unable to show the benefit of starting β -blockers in the perioperative setting in patients with diabetes. Very recently, the relationship between the use of β -blockers and all-cause mortality was evaluated in patients with diabetes mellitus and those without⁷⁶. The mortality of diabetic patients taking β -blockers was higher compared with those diabetics who did not take β -blockers (hazard ratio 1.65, 95% confidence interval 1.13–2.40; $P = 0.009$). Similar results were found when only β 1-selective β -blockers were taken into analysis. However, all-cause mortality was significantly lower in non-diabetic patients taking β 1-selective β -blockers compared with non-diabetic participants not taking β -blockers ($P = 0.01$). Although the authors cannot explain the exact reason for these observed differences, they hypothesize that adverse effects on glucose metabolism (more hypoglycemia and hypoglycemia unawareness in diabetics) and weight gain induced by β -blockers may result in an increased risk of mortality.

What is true from a cardioprotective perspective in non-diabetics may not necessarily be relevant in patients with diabetes mellitus. Further research in this field is mandatory before drawing any firm conclusions.

Aging

Ischemia-reperfusion injury and cardioprotection in the aged myocardium

Aging induces structural and functional changes in the heart, as in all other human organs, resulting in greater damage of the aging

heart owing to the deleterious effects of ischemia-reperfusion injury⁷⁷⁻⁷⁹. Moreover, experimental studies have shown that the aging myocardium is less responsive to ischemic preconditioning⁸⁰⁻⁸⁴. This reduced preconditioning effect in the aged myocardium has also been observed with inhalational anesthetics^{85,86}.

A recent study specifically investigated the influence of aging on the release of cardioprotective humoral factors after RIPC and the cardioprotective effects of RIPC on aged myocardium⁸⁷. From the data obtained in this study, it appears that the release of humoral factors after RIPC is age-dependent and that the RIPC-induced humoral factors are cardioprotective also in the aged heart. These results emphasize the complex mechanisms involved in the cardioprotective effects of RIPC and might partly explain the disappointing observation in large clinical trials aiming to show the perioperative cardioprotective effects of RIPC^{70,71}.

Studies of perioperative cardioprotection taking into account patient's age

Despite the existing evidence of experimental trials that the aged myocardium is less responsive to any type of cardioprotection, few clinical studies have clearly analyzed the possible relation between the extent of perioperative cardioprotection and age.

From the available clinical data, it is not clear whether considerable cardioprotection can be achieved in the elderly^{70,88-91}. Of note, it remains difficult to give an exact definition of "old myocardium". More than the chronological age of the patient, conditions that influence the endogenous protective mechanisms of the myocardium might affect the response of the heart to various protective mechanisms. Physical activity has been shown to be among such protective mechanisms^{92,93}. Future trials need to take into account these aspects.

Comedication

Elderly people often take various cardiovascular (and other) medications. These treatments alone or in combination may interfere with cardioprotective mechanisms. Some of these drug therapies have been discussed in this review article. Other routinely used medications that have been studied in the context of perioperative cardioprotection and that will be further discussed in this review article are (1) statins, (2) angiotensin-converting enzyme inhibitors (ACE-Is)/angiotensin receptor blockers, (3) calcium channel blockers, and (4) nitrates. The interaction of these drugs with some of the perioperative cardioprotective strategies has been studied in different trials.

Statins. In recent years, much interest has been given to the pleiotropic effects of statins, contributing to their cardioprotective effects⁹⁴. The cardioprotective properties of statins have been evaluated in numerous trials resulting in a considerable number of meta-analyses and systematic reviews. It seems that perioperative statin therapy is associated with a lower incidence of postoperative myocardial infarction in non-cardiac surgery

but not in cardiac surgery. The pathophysiology of perioperative myocardial ischemia is different in non-cardiac⁹⁵ and cardiac surgery, which may explain the discrepant results between the two surgical groups.

Based on the evidence available in 2014, the European Society of Cardiology/European Society of Anaesthesiology (ESC/ESA) guidelines on non-cardiac surgery have a class I recommendation for perioperative continuation of statins, favoring statins with a long half-life or extended-release formulation. A class IIa recommendation has been given for preoperative initiation of statin therapy in patients undergoing vascular surgery and ideally this should be performed at least 2 weeks before surgery⁹⁶.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A large meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors in patients with hypertension showed that all-cause mortality was significantly reduced with these drugs compared with controls⁹⁷. However, the observed treatment effect resulted from the ACE-Is. This decrease in mortality could not be demonstrated with angiotensin receptor blockers⁹⁷.

Both drugs, when used in the perioperative period, can induce mild to severe hypotension, which can be resistant to vasopressors in some patients. Therefore, when these drugs are used for hypertension, their withdrawal 24 hours before surgery has been recommended. This is a class IIa recommendation from ESC/ESA guidelines on non-cardiac surgery⁹⁶. These guidelines recommend continuation of ACE-Is or angiotensin receptor blockers under close monitoring during non-cardiac surgery in stable patients with heart failure and left ventricular systolic dysfunction (IIa).

Calcium channel blockers. Few well-powered studies have evaluated the beneficial effects of calcium channel blockers in the perioperative period. The safety and efficacy of these drugs have been questioned⁹⁸.

The use of dihydropyridine calcium channel blockers has been associated with 30-day mortality in patients with acute or elective aortic aneurysm surgery⁹⁹. In this regard, the 2014 ESC/ESA guidelines recommend that the continuation or introduction of heart rate-reducing calcium channel blockers may be considered in patients not tolerating β -blockers⁹⁶.

Nitrates. In recent years, there has been increasing interest in the cardioprotective effects of nitrates. Previous studies have shown that intravenous injection of nicorandil can decrease the incidence of myocardial injury after percutaneous coronary intervention^{100,101}. Otherwise, a single oral dose of nicorandil showed cardioprotective effects after coronary angioplasty¹⁰². The preconditioning actions of nitroglycerin have been demonstrated in specific clinical scenarios^{103,104}. Leesar *et al.*¹⁰³ showed, for the first time, that 4-hour intravenous administration of nitroglycerin protected human myocardium against ischemia 24 hours after its administration¹⁰⁵. Nevertheless, the endothelial

preconditioning effects of a single dose of nitroglycerin are lost after a prolonged exposure to nitroglycerin, limiting the beneficial effects of long-term prophylactic nitrate therapy¹⁰⁶. In a small study, its acute administration did not interfere with remote ischemic conditioning¹⁰⁷. Otherwise, two large clinical studies failed to show any possible benefit in terms of mortality with the use of nitrates in the setting of acute myocardial injury with thrombolytic therapy^{108,109}.

Conclusions

Prevention of perioperative morbidity and mortality is a challenge in patients with diabetes and in the elderly. Patients with diabetes are at high risk of ischemic heart disease and are vulnerable to the effects of myocardial ischemia-reperfusion injury. Chronic metformin treatment has shown promising results regarding cardiovascular outcome in patients with diabetes. Its perioperative cardioprotective effects still need to be investigated. Nevertheless, its withdrawal before any surgery may not be justified, as the risk of lactic acidosis is extremely low. The safety and efficacy of RIPC in the setting of diabetes need to be elucidated. Otherwise, β -blockers may not have the same beneficial effects in diabetic patients compared with non-diabetics. Their use should be carefully evaluated in diabetic patients who have a maximum medical treatment.

Advanced age is often associated with cardiovascular morbidity. Currently, there is no clear evidence whether elderly patients

are less responsive to routine perioperative cardioprotective strategies. Comedication is often observed in older patients. Current evidence strongly supports the continuation of statins in the perioperative period. ACE-Is reduce all-cause mortality when used for hypertension and should only be stopped 24 hours before surgery to avoid hypotension.

In conclusion, the translation of cardioprotection into the clinical setting where advanced age and various comorbidities are common calls for well-designed experimental and clinical studies.

Abbreviations

ACE-I, angiotensin-converting enzyme inhibitor; AMPK, adenosine monophosphate-activated protein kinase; eNOS, endothelial nitric oxide synthase; ERICCA, Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery; ESA, European Society of Anaesthesiology; ESC, European Society of Cardiology; K_{ATP} , ATP-dependent potassium; mPTP, mitochondrial permeability transition pore; NO, nitric oxide; RIPC, remote ischemic preconditioning

Grant information

The author(s) declared that no grants were involved in supporting this work.


References



1. **Our Surveys & Programs / Population Projections.** [Reference Source](#)
2. Etzioni DA, Liu JH, O'Connell JB, *et al.*: **Elderly patients in surgical workloads: a population-based analysis.** *Am Surg.* 2003; **69**(11): 961–5. [PubMed Abstract](#)
3. Benjamin EJ, Virani SS, Callaway CW, *et al.*: **Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.** *Circulation.* 2018; **137**(12): e67–e492. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
4. Wild S, Roglic G, Green A, *et al.*: **Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.** *Diabetes Care.* 2004; **27**(5): 1047–53. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Haffner SM, Lehto S, Rönkämaa T, *et al.*: **Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.** *N Engl J Med.* 1998; **339**(4): 229–34. [PubMed Abstract](#) | [Publisher Full Text](#)
6. De Hert SG, Preckel B, Hollmann MW, *et al.*: **Drugs mediating myocardial protection.** *Eur J Anaesthesiol.* 2009; **26**(12): 985–95. [PubMed Abstract](#) | [Publisher Full Text](#)
7. De Hert SG, Preckel B, Schlack WS: **Update on inhalational anaesthetics.** *Curr Opin Anaesthesiol.* 2009; **22**(4): 491–5. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Chow KY, Liu SE, Irwin MG: **New therapy in cardioprotection.** *Curr Opin Anaesthesiol.* 2015; **28**(4): 417–23. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Xia Z, Li H, Irwin MG: **Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans.** *Br J Anaesth.* 2016; **117** Suppl 2: ii44–ii62. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
10. Zaugg M, Lucchinetti E, Behmanesh S, *et al.*: **Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications.** *Curr Pharm Des.* 2014; **20**(36): 5706–26. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Leung MK, Irwin MG: **Perioperative cardioprotection.** *F1000Prime Rep.* 2013; **5**: 7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Heusch G, Gersh BJ: **The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.** *Eur Heart J.* 2017; **38**(11): 774–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
13. Hausenloy DJ, Botker HE, Engstrom T, *et al.*: **Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.** *Eur Heart J.* 2017; **38**(13): 935–41. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
14. Thielmann M, Sharma V, Al-Attar N, *et al.*: **ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery.** *Eur Heart J.* 2017; **38**(31): 2392–411. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
15. Lejay A, Fang F, John R, *et al.*: **Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus.** *J Mol Cell Cardiol.* 2016; **91**: 11–22. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Ibáñez B, Heusch G, Ovize M, *et al.*: **Evolving therapies for myocardial ischemia/reperfusion injury.** *J Am Coll Cardiol.* 2015; **65**(14): 1454–71. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Giordano FJ: **Oxygen, oxidative stress, hypoxia, and heart failure.** *J Clin Invest.* 2005; **115**(3): 500–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Gu W, Pagel PS, Warltier DC, *et al.*: **Modifying cardiovascular risk in diabetes mellitus.** *Anesthesiology.* 2003; **98**(3): 774–9. [PubMed Abstract](#)
19. Miki T, Itoh T, Sunaga D, *et al.*: **Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.** *Cardiovasc Diabetol.* 2012; **11**: 67. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Chen QL, Gu EW, Zhang L, *et al.*: **Diabetes mellitus abrogates the cardioprotection of sufentanil against ischaemia/reperfusion injury by altering**

- glucogen synthase kinase-3 β . *Acta Anaesthesiol Scand*. 2013; 57(2): 236–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Drenger B, Ostrovsky IA, Barak M, *et al.*: **Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition.** *Anesthesiology*. 2011; 114(6): 1364–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Yetgin T, Magro M, Manintveld OC, *et al.*: **Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning.** *Basic Res Cardiol*. 2014; 109(2): 403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. **F** Wider J, Undyala VVR, Whittaker P, *et al.*: **Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.** *Basic Res Cardiol*. 2018; 113(3): 16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 24. Kersten JR, Montgomery MW, Ghassemi T, *et al.*: **Diabetes and hyperglycemia impair activation of mitochondrial K_{ATP} channels.** *Am J Physiol Heart Circ Physiol*. 2001; 280(4): H1744–H1750.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. **F** Fujita Y, Inagaki N: **Metformin: New Preparations and Nonglycemic Benefits.** *Curr Diab Rep*. 2017; 17(1): 5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 26. **F** Varjabedian L, Bourji M, Pourafkari L, *et al.*: **Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction.** *Am J Cardiovasc Drugs*. 2018; 18(3): 181–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 27. Mount PF, Kemp BE, Power DA: **Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation.** *J Mol Cell Cardiol*. 2007; 42(2): 271–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. El Messaoudi S, Rongen GA, Riksen NP: **Metformin therapy in diabetes: the role of cardioprotection.** *Curr Atheroscler Rep*. 2013; 15(4): 314.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. El Messaoudi S, Rongen GA, de Boer RA, *et al.*: **The cardioprotective effects of metformin.** *Curr Opin Lipidol*. 2011; 22(6): 445–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Solskov L, Lofgren B, Kristiansen SB, *et al.*: **Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration.** *Basic Clin Pharmacol Toxicol*. 2008; 103(1): 82–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Bhamra GS, Hausenloy DJ, Davidson SM, *et al.*: **Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.** *Basic Res Cardiol*. 2008; 103(3): 274–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Paiva M, Riksen NP, Davidson SM, *et al.*: **Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.** *J Cardiovasc Pharmacol*. 2009; 53(5): 373–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Calvert JW, Gundewar S, Jha S, *et al.*: **Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.** *Diabetes*. 2008; 57(3): 696–705.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Zhang L, He H, Balschi JA: **Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.** *Am J Physiol Heart Circ Physiol*. 2007; 293(1): H457–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Whittington HJ, Hall AR, McLaughlin CP, *et al.*: **Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.** *Cardiovasc Drugs Ther*. 2013; 27(1): 5–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Techiryanyan G, Weil BR, Palka BA, *et al.*: **Effect of Intracoronary Metformin on Myocardial Infarct Size in Swine.** *Circ Res*. 2018; 123(8): 986–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Bell RM, Botker HE, Carr RD, *et al.*: **9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection.** *Basic Res Cardiol*. 2016; 111(4): 41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Heusch G, Skyschally A, Kleinbongard P: **Translation, Translation, Translation.** *Circ Res*. 2018; 123(8): 931–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Heusch G: **Critical Issues for the Translation of Cardioprotection.** *Circ Res*. 2017; 120(9): 1477–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. **F** Zaugg M, Wang L, Zhang L, *et al.*: **Choice of anesthetic combination determines Ca^{2+} leak after ischemia-reperfusion injury in the working rat heart: favorable versus adverse combinations.** *Anesthesiology*. 2012; 116(3): 648–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 41. Kottenberg E, Musiolik J, Thielmann M, *et al.*: **Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting.** *J Thorac Cardiovasc Surg*. 2014; 147(1): 376–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Kottenberg E, Thielmann M, Bergmann L, *et al.*: **Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial.** *Acta Anaesthesiol Scand*. 2012; 56(1): 30–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Nichols GA, Koro CE, Gullion CM, *et al.*: **The incidence of congestive heart failure associated with antidiabetic therapies.** *Diabetes Metab Res Rev*. 2005; 21(1): 51–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Masoudi FA, Inzucchi SE, Wang Y, *et al.*: **Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study.** *Circulation*. 2005; 111(5): 583–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Eurich DT, Majumdar SR, McAlister FA, *et al.*: **Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure.** *Diabetes Care*. 2005; 28(10): 2345–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Evans JM, Doney AS, AlZadjali MA, *et al.*: **Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus.** *Am J Cardiol*. 2010; 106(7): 1006–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Romero SP, Andrey JL, Garcia-Egido A, *et al.*: **Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community.** *Int J Cardiol*. 2013; 166(2): 404–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Andersson C, Olesen JB, Hansen PR, *et al.*: **Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.** *Diabetologia*. 2010; 53(12): 2546–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Aguilar D, Chan W, Bozkurt B, *et al.*: **Metformin use and mortality in ambulatory patients with diabetes and heart failure.** *Circ Heart Fail*. 2011; 4(1): 53–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Mellbin LG, Malmberg K, Norhammar A, *et al.*: **The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.** *Eur Heart J*. 2007; 29(2): 166–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Roussel R, Travert F, Pasquet B, *et al.*: **Metformin use and mortality among patients with diabetes and atherothrombosis.** *Arch Intern Med*. 2010; 170(21): 1892–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Ekström N, Schiöler L, Svensson AM, *et al.*: **Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.** *BMJ Open*. 2012; 2(4): pii: e001076.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Lexis CP, Wieringa WG, Hiemstra B, *et al.*: **Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction.** *Cardiovasc Drugs Ther*. 2014; 28(2): 163–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. **F** Claessen M, Gillard P, De Smet F, *et al.*: **Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study.** *J Clin Endocrinol Metab*. 2016; 101(2): 461–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 55. Preiss D, Lloyd SM, Ford I, *et al.*: **Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.** *Lancet Diabetes Endocrinol*. 2014; 2(2): 116–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Lexis CP, van der Horst IC, Lipsic E, *et al.*: **Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.** *JAMA*. 2014; 311(15): 1526–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. **F** Al Ali L, Hartman MT, Lexis CP, *et al.*: **The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.** *PLoS One*. 2016; 11(12): e0168340.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 58. El Messaoudi S, Nederlof R, Zuurbier CJ, *et al.*: **Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial.** *Lancet Diabetes Endocrinol*. 2015; 3(8): 615–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. **F** Hartman MHT, Prins JKB, Schurer RAJ, *et al.*: **Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.** *Clin Res Cardiol*. 2017; 106(12): 939–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 60. **F** Tran KL, Park YI, Pandya S, *et al.*: **Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.** *Am Health Drug Benefits*. 2017; 10(4): 178–88.
[PubMed Abstract](#) | [Free Full Text](#) | [F1000 Recommendation](#)

61. Ahmed HM, Khraishah H, Cho L: **Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.** *Eur Heart J.* 2018; **39**(25): 2368–75. [PubMed Abstract](#) | [Publisher Full Text](#)
62. Bethel MA, Patel RA, Merrill P, *et al.*: **Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.** *Lancet Diabetes Endocrinol.* 2018; **6**(2): 105–13. [PubMed Abstract](#) | [Publisher Full Text](#)
63. **F** Giugliano D, Meier JJ, Esposito K: **Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.** *Diabetes Obes Metab.* 2019; **21**(5): 1081–1087. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. **F** Kleinbongard P, Skyschally A, Heusch G: **Cardioprotection by remote ischemic conditioning and its signal transduction.** *Pflugers Arch.* 2017; **469**(2): 159–81. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
65. Heusch G, Bøtker HE, Przyklenk K, *et al.*: **Remote Ischemic Conditioning.** *J Am Coll Cardiol.* 2015; **65**(2): 177–95. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. **F** Heusch G: **25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome.** *Basic Res Cardiol.* 2018; **113**(3): 15. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
67. **F** Chong J, Bulluck H, Yap EP, *et al.*: **Remote ischemic conditioning in ST-segment elevation myocardial infarction - an update.** *Cond Med.* 2018; **1**(5): 13–22. [PubMed Abstract](#) | [Free Full Text](#) | [F1000 Recommendation](#)
68. Kottenberg E, Thielmann M, Kleinbongard P, *et al.*: **Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.** *Acta Anaesthesiol Scand.* 2014; **58**(4): 453–62. [PubMed Abstract](#) | [Publisher Full Text](#)
69. **F** Moretti C, Cerrato E, Cavallero E, *et al.*: **The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial.** *Int J Cardiol.* 2018; **257**: 1–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
70. Hausenloy DJ, Candilio L, Evans R, *et al.*: **Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery.** *N Engl J Med.* 2015; **373**(15): 1408–17. [PubMed Abstract](#) | [Publisher Full Text](#)
71. Meybohm P, Bein B, Brosteanu O, *et al.*: **A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.** *N Engl J Med.* 2015; **373**(15): 1397–407. [PubMed Abstract](#) | [Publisher Full Text](#)
72. Heusch G, Gersh BJ: **ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not!** *Eur Heart J.* 2016; **37**(2): 200–2. [PubMed Abstract](#) | [Publisher Full Text](#)
73. Fihn SD, Gardin JM, Abrams J, *et al.*: **2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.** *J Am Coll Cardiol.* 2012; **60**(24): e44–e164. [PubMed Abstract](#) | [Publisher Full Text](#)
74. Yancy CW, Jessup M, Bozkurt B, *et al.*: **2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.** *J Am Coll Cardiol.* 2013; **62**(16): e147–239. [PubMed Abstract](#) | [Publisher Full Text](#)
75. **F** Juul AB, Wetterslev J, Gluud C, *et al.*: **Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial.** *BMJ.* 2006; **332**(7556): 1482. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
76. **F** Tsujimoto T, Kajio H, Shapiro MF, *et al.*: **Risk of All-Cause Mortality in Diabetic Patients Taking β -Blockers.** *Mayo Clin Proc.* 2018; **93**(4): 409–18. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
77. Jahangir A, Sagar S, Terzic A: **Aging and cardioprotection.** *J Appl Physiol (1985).* 2007; **103**(6): 2120–8. [PubMed Abstract](#) | [Publisher Full Text](#)
78. Navarro A, Boveris A: **The mitochondrial energy transduction system and the aging process.** *Am J Physiol Cell Physiol.* 2007; **292**(2): C670–86. [PubMed Abstract](#) | [Publisher Full Text](#)
79. Ataka K, Chen D, Levitsky S, *et al.*: **Effect of aging on intracellular Ca²⁺, pHi, and contractility during ischemia and reperfusion.** *Circulation.* 1992; **86**(5 Suppl): II371–6. [PubMed Abstract](#)
80. Abete P, Ferrara N, Cioppa A, *et al.*: **Preconditioning does not prevent postischemic dysfunction in aging heart.** *J Am Coll Cardiol.* 1996; **27**(7): 1777–86. [PubMed Abstract](#) | [Publisher Full Text](#)
81. Tani M, Suganuma Y, Hasegawa H, *et al.*: **Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts.** *Circulation.* 1997; **95**(11): 2559–66. [PubMed Abstract](#) | [Publisher Full Text](#)
82. Bartling B, Friedrich I, Silber RE, *et al.*: **Ischemic preconditioning is not cardioprotective in senescent human myocardium.** *Ann Thorac Surg.* 2003; **76**(1): 105–11. [PubMed Abstract](#) | [Publisher Full Text](#)
83. Boengler K, Konietzka I, Buechert A, *et al.*: **Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43.** *Am J Physiol Heart Circ Physiol.* 2007; **292**(4): H1764–9. [PubMed Abstract](#) | [Publisher Full Text](#)
84. Boengler K, Schulz R, Heusch G: **Loss of cardioprotection with ageing.** *Cardiovasc Res.* 2009; **83**(2): 247–61. [PubMed Abstract](#) | [Publisher Full Text](#)
85. Nguyen LT, Rebecchi MJ, Moore LC, *et al.*: **Attenuation of isoflurane-induced preconditioning and reactive oxygen species production in the senescent rat heart.** *Anesth Analg.* 2008; **107**(3): 776–82. [PubMed Abstract](#) | [Publisher Full Text](#)
86. Sniecinski R, Liu H: **Reduced efficacy of volatile anesthetic preconditioning with advanced age in isolated rat myocardium.** *Anesthesiology.* 2004; **100**(3): 589–97. [PubMed Abstract](#) | [Publisher Full Text](#)
87. **F** Heinen A, Behmenburg F, Aytulun A, *et al.*: **The release of cardioprotective humoral factors after remote ischemic preconditioning in humans is age- and sex-dependent.** *J Transl Med.* 2018; **16**(1): 112. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
88. Wu ZK, Pehkonen E, Laurikka J, *et al.*: **The protective effects of preconditioning decline in aged patients undergoing coronary artery bypass grafting.** *J Thorac Cardiovasc Surg.* 2001; **122**(5): 972–8. [PubMed Abstract](#) | [Publisher Full Text](#)
89. Lee TM, Su SF, Chou TF, *et al.*: **Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty.** *Circulation.* 2002; **105**(3): 334–40. [PubMed Abstract](#) | [Publisher Full Text](#)
90. De Hert S, Viasselaers D, Barbé R, *et al.*: **A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery.** *Anaesthesia.* 2009; **64**(9): 953–60. [PubMed Abstract](#) | [Publisher Full Text](#)
91. **F** Kleinbongard P, Neuhäuser M, Thielmann M, *et al.*: **Confounders of Cardioprotection by Remote Ischemic Preconditioning in Patients Undergoing Coronary Artery Bypass Grafting.** *Cardiology.* 2016; **133**(2): 128–33. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
92. Abete P, Ferrara N, Cacciatore F, *et al.*: **High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients.** *J Am Coll Cardiol.* 2001; **38**(5): 1357–65. [PubMed Abstract](#) | [Publisher Full Text](#)
93. Thiele RH: **Subcellular Energetics and Metabolism: Potential Therapeutic Applications.** *Anesth Analg.* 2017; **124**(6): 1872–85. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Mihos CG, Pineda AM, Santana O: **Cardiovascular effects of statins, beyond lipid-lowering properties.** *Pharmacol Res.* 2014; **88**: 12–9. [PubMed Abstract](#) | [Publisher Full Text](#)
95. De Hert S, Moerman A, De Baerdemaeker L: **Postoperative complications in cardiac patients undergoing noncardiac surgery.** *Curr Opin Crit Care.* 2016; **22**(4): 357–64. [PubMed Abstract](#) | [Publisher Full Text](#)
96. Kristensen SD, Knutti J, Saraste A, *et al.*: **2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).** *Eur J Anaesthesiol.* 2014; **31**(10): 517–73. [PubMed Abstract](#) | [Publisher Full Text](#)
97. **F** van Vark LC, Bertrand M, Akkerhuis KM, *et al.*: **Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.** *Eur Heart J.* 2012; **33**(16): 2088–97. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
98. Opie LH, Yusuf S, Kübler W: **Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.** *Prog Cardiovasc Dis.* 2000; **43**(2): 171–96. [PubMed Abstract](#) | [Publisher Full Text](#)
99. Kertai MD, Westerhout CM, Varga KS, *et al.*: **Dihydropyridine calcium-channel blockers and perioperative mortality in aortic aneurysm surgery.** *Br J Anaesth.* 2008; **101**(4): 458–65. [PubMed Abstract](#) | [Publisher Full Text](#)
100. Ueda H, Nakayama Y, Tsumura K, *et al.*: **Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction.** *Can J Cardiol.* 2004; **20**(6): 625–9. [PubMed Abstract](#)
101. Isono T, Kamihata H, Sutani Y, *et al.*: **Nicorandil suppressed myocardial injury**

- after percutaneous coronary intervention. *Int J Cardiol.* 2008; **123**(2): 123–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Kato T, Kamiyama T, Maruyama Y, *et al.*: Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. *Am Heart J.* 2001; **141**(6): 940–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Leesar MA, Stoddard MF, Dawn B, *et al.*: Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. *Circulation.* 2001; **103**(24): 2935–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
104. Jneid H, Chandra M, Alshaher M, *et al.*: Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. *Circulation.* 2005; **111**(20): 2565–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Heusch G: Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? *Circulation.* 2001; **103**(24): 2876–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
106.  Gori T, Dragoni S, Di Stolfo G, *et al.*: Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human *in vivo* study. *Am J Physiol Heart Circ Physiol.* 2010; **298**(2): H340–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
107. Kleinbongard P, Thielmann M, Jakob H, *et al.*: Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. *Cardiovasc Drugs Ther.* 2013; **27**(4): 359–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. *Lancet.* 1994; **343**(8906): 1115–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
109. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet.* 1995; **345**(8951): 669–85.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Referee Status:  

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- 1 **Gerd Heusch** Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany
Competing Interests: No competing interests were disclosed.
- 2 **Arthur Bouwman** Department of Anesthesiology, Pain Medicine and Intensive Care, Catharina Hospital, Eindhoven, 5623, The Netherlands
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research